Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Synlogic, Inc. - Common Stock (NQ:SYBX)

1.150 +0.030 (+2.68%)
Streaming Delayed Price Updated: 3:03 PM EDT, Apr 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Synlogic, Inc. - Common Stock

< Previous 1 2 Next >
Synlogic Reports Third Quarter 2024 Financial Results
From Synlogic, Inc.
Via GlobeNewswire
Synlogic Reports Second Quarter 2024 Financial Results
From Synlogic, Inc.
Via GlobeNewswire
Synlogic Reports First Quarter 2024 Financial Results
From Synlogic, Inc.
Via GlobeNewswire
Synlogic Reports Fourth Quarter and Full Year 2023 Financial Results
From Synlogic, Inc.
Via GlobeNewswire
Synlogic Adopts Limited Duration Stockholders Rights Plan
Engages Ladenburg Thalmann as financial advisor to assist with previously announced strategic review process 
From Synlogic, Inc.
Via GlobeNewswire
Synlogic Announces Decision to Discontinue Synpheny-3 Study and Provides Corporate Update
From Synlogic, Inc.
Via GlobeNewswire
Synlogic Announces Publication of Preclinical and Clinical Data for SYNB1353 as a Potential Treatment for Classical Homocystinuria
From Synlogic, Inc.
Via GlobeNewswire
Sidoti Events, LLC's Virtual January Micro-Cap Conference
Via ACCESSWIRE
Synlogic Provides Corporate Update and Outlook for 2024
From Synlogic, Inc.
Via GlobeNewswire
Synlogic Announces Contract with the Air Force Research Lab
- Selection of Synlogic reflects Company’s leadership in process development and manufacturing of therapeutics based on synthetic biology - 
From Synlogic, Inc.
Via GlobeNewswire
Synlogic Announces Abstract Accepted for Poster Presentation at the International Conference on Microbiome Engineering 2023
From Synlogic, Inc.
Via GlobeNewswire
Synlogic Reports Third Quarter 2023 Financial Results and Provides Corporate Update
From Synlogic, Inc.
Via GlobeNewswire
Synlogic Achieves Research Milestone and Earns $2.5 Million Milestone Payment from Roche Collaboration
From Synlogic, Inc.
Via GlobeNewswire
Synlogic Announces Closing of $21.0 Million Underwritten Public Offering
From Synlogic, Inc.
Via GlobeNewswire
Synlogic Announces Pricing of $21.0 Million Underwritten Public Offering
From Synlogic, Inc.
Via GlobeNewswire
Synlogic Announces Publication of Synpheny-1 Phase 2 Study of Synthetic Biotic for Phenylketonuria in Nature Metabolism
From Synlogic, Inc.
Via GlobeNewswire
Synlogic Announces Reverse Stock Split
From Synlogic, Inc.
Via GlobeNewswire
Synlogic to Participate in Chardan’s Genetic Medicines Conference
From Synlogic, Inc.
Via GlobeNewswire
Synlogic Announces CEO Aoife Brennan Named to PharmaVoice 100
From Synlogic, Inc.
Via GlobeNewswire
Synlogic Reports Second Quarter 2023 Financial Results and Provides Business Update
Recent milestones include initiation of the pivotal Phase 3 trial, Synpheny-3, and receipt of Fast Track designation for labafenogene marselecobac as a potential treatment for PKU 
From Synlogic, Inc.
Via GlobeNewswire
Synlogic Granted Fast Track Designation from FDA for labafenogene marselecobac (SYNB1934) for Treatment of Phenylketonuria
From Synlogic, Inc.
Via GlobeNewswire
Synlogic Announces International Nonproprietary Name Selection for SYNB1934
From Synlogic, Inc.
Via GlobeNewswire
Synlogic Announces Participation in SVB Securities Healthcare Therapeutics Forum
From Synlogic, Inc.
Via GlobeNewswire
Synlogic Reminds Stockholders of 2023 Annual General Meeting Details
From Synlogic, Inc.
Via GlobeNewswire
Synlogic Announces Initiation of Synpheny-3 Global, Pivotal Phase 3 Study Evaluating SYNB1934 for Treatment of Phenylketonuria
From Synlogic, Inc.
Via GlobeNewswire
Synlogic Announces Data Presentations at the 2023 Synthetic Biology: Engineering, Evolution & Design (SEED) Conference
From Synlogic, Inc.
Via GlobeNewswire
Synlogic to Present at the Jefferies Global Healthcare Conference
From Synlogic, Inc.
Via GlobeNewswire
Synlogic Reports First Quarter 2023 Financial Results and Provides Business Update
From Synlogic, Inc.
Via GlobeNewswire
Synlogic Receives Orphan Drug Designation from FDA for SYNB1934 for Treatment of Phenylketonuria
From Synlogic, Inc.
Via GlobeNewswire
Synlogic Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates
From Synlogic, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.